Immunovant, Inc.
↗Durham, North Carolina, USA
Immunovant is a clinical-stage immunology company dedicated to developing innovative, targeted therapies for patients with autoimmune diseases. The company is a trailblazer in anti-FcRn technology, focusing on addressing diseases mediated by pathogenic immunoglobulin G (IgG) antibodies.
Immunovant is a member of the Roivant group, which provides strategic support and synergistic collaborations. The company's primary focus is on developing best-in-class FcRn inhibitors, with a pipeline that includes candidates like IMVT-1402, aimed at treating conditions such as Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren's disease, and rheumatoid arthritis.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immunology / Autoimmune Diseases
SIZE & FINANCIALS
Employees:201-500
Founded:2018
Ownership:public
Status:operating
FUNDING
Investors:Roivant Sciences
STOCK
Exchange:NASDAQ
Ticker:IMVT
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Monoclonal antibody
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Roivant Sciences (Majority Shareholder)
Key Partnerships:HanAll Biopharma (Development partner for batoclimab)
COMPETITION
Position:Emerging
Competitors:Argenx, Alexion Pharmaceuticals, UCB
LEADERSHIP
Key Executives:
Pete Salzmann - CEO
LINKS
Website:immunovant.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Immunovant, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Immunovant, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.